{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu J"],"funding":["Guangzhou Science and Technology Program","National Natural Science Foundation of China","Sun Yat-Sen Clinical Research Incubation Program","Sun Yat-Sen Clinical Research 5010 Program"],"pagination":["e078049"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11293409"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(7)"],"pubmed_abstract":["

Introduction

Postoperative radiotherapy in patients with breast cancer with one to three lymph node metastases, particularly within the pT1-2N1M0 cohort with a low clinical risk of local-regional recurrence (LRR), has incited a discourse surrounding personalised treatment strategies. Multigene testing for Recurrence Index (RecurIndex) model capably differentiates patients based on their level of LRR risk. This research aims to validate whether a more aggressive treatment approach can enhance clinical outcomes in N1 patients who possess a clinically low risk of LRR, yet a high RecurIndex-determined risk of LRR. Specifically, this entails postoperative whole breast irradiation combined with regional lymph node irradiation (RNI) following breast-conserving surgery or chest wall irradi"],"journal":["BMJ open"],"pubmed_title":["RecurIndex-Guided postoperative radiotherapy with or without Avoidance of Irradiation of regional Nodes in 1-3 node-positive breast cancer (RIGAIN): a study protocol for a multicentre, open-label, randomised controlled prospective, phase III trial."],"pmcid":["PMC11293409"],"funding_grant_id":["82173232","SYS-C-202006","SYS-5010-202303"],"pubmed_authors":["Liu J","Zhang AD","Chen J","Liang Z","Zhang N","Wang F","Lin X","Zhou W","Hou Y","Lan X","Ye X","Huang S","Zhao L","Ding R","Tan Y","Zhang X","Guo JG","Huang X","Wang X","Wang Y","Xu X","Bi Z"],"additional_accession":[]},"is_claimable":false,"name":"RecurIndex-Guided postoperative radiotherapy with or without Avoidance of Irradiation of regional Nodes in 1-3 node-positive breast cancer (RIGAIN): a study protocol for a multicentre, open-label, randomised controlled prospective, phase III trial.","description":"

Introduction

Postoperative radiotherapy in patients with breast cancer with one to three lymph node metastases, particularly within the pT1-2N1M0 cohort with a low clinical risk of local-regional recurrence (LRR), has incited a discourse surrounding personalised treatment strategies. Multigene testing for Recurrence Index (RecurIndex) model capably differentiates patients based on their level of LRR risk. This research aims to validate whether a more aggressive treatment approach can enhance clinical outcomes in N1 patients who possess a clinically low risk of LRR, yet a high RecurIndex-determined risk of LRR. Specifically, this entails postoperative whole breast irradiation combined with regional lymph node irradiation (RNI) following breast-conserving surgery or chest wall irradi","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-03T00:37:51.049Z","creation":"2024-11-15T21:24:02.582Z"},"accession":"S-EPMC11293409","cross_references":{"pubmed":["39079921"],"doi":["10.1136/bmjopen-2023-078049"]}}